Checkpoint Therapeutics (FRA:CZTA) Change In Receivables : €0.03 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics Change In Receivables?

Checkpoint Therapeutics's change in receivables for the quarter that ended in Sep. 2024 was €0.04 Mil. It means Checkpoint Therapeutics's Accounts Receivable declined by €0.04 Mil from Jun. 2024 to Sep. 2024 .

Checkpoint Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.07 Mil. It means Checkpoint Therapeutics's Accounts Receivable declined by €0.07 Mil from Dec. 2022 to Dec. 2023 .

Checkpoint Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Checkpoint Therapeutics's liquidation value for the three months ended in Sep. 2024 was €-11.77 Mil.

Checkpoint Therapeutics Change In Receivables Historical Data

The historical data trend for Checkpoint Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Change In Receivables Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

1.36

0.01

-0.05

0.07

Checkpoint Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	0.03	-	-0.04	0.04

Checkpoint Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03 Mil.

Checkpoint Therapeutics (FRA:CZTA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Checkpoint Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Checkpoint Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Checkpoint Therapeutics's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.237	-	16.01	+	0.75 * 0	+	0.5 * 0
=	-11.77

Checkpoint Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (FRA:CZTA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CKPT:USA

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics Headlines

No Headlines